Junxuan Yi

Dr. Junxuan Yi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MWMingwei Wang
Mingwei Wang
JYJunxuan Yi
Junxuan Yi
HGHui Gao
Hui Gao
XWXinfeng Wei
Xinfeng Wei
WXWeiqiang Xu
Weiqiang Xu
SJShunzi Jin
Shunzi Jin
Despite the importance of radiation therapy as a non-surgical treatment for non-small cell lung cancer (NSCLC), radiation resistance has always been a concern, due to poor patient response and prognosis. Therefore, it is crucial to uncover novel targets to enhance radiotherapy and investigate the mechanisms underlying radiation resistance. Previously, we demonstrated that NRP1 was connected to radiation resistance in NSCLC cells. In the present study, bioinformatics analysis of constructed radiation-resistant A549 and H1299 cell models revealed that transcription coactivator YAP is a significant factor in cell proliferation and metastasis. However, there has been no evidence linking YAP and NRP1 to date. In this research, we have observed that YAP contributes to radiation resistance in NSCLC cells by stimulating cell proliferation, migration, and invasion. Mechanistically, YAP dephosphorylation after NSCLC cell radiation. YAP acts as a transcription co-activator by binding to the transcription factor TEAD4, facilitating TEAD4 to bind to the NRP1 promoter region and thereby increasing NRP1 expression. NRP1 has been identified as a new target gene for YAP/TEAD4. Notably, when inhibiting YAP binds to TEAD4, it inhibits NRP1 expression, and Rescue experiments show that YAP/TEAD4 influences NRP1 to regulate cell proliferation, metastasis and leading to radiation resistance generation. According to these results, YAP/TEAD4/NRP1 is a significant mechanism for radioresistance and can be utilized as a target for enhancing radiotherapy efficacy.

10 August 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
RWRui Wang
Rui Wang
JYJunxuan Yi
Junxuan Yi
HGHui Gao
Hui Gao
XWXinfeng Wei
Xinfeng Wei
LSLihong Shao
Lihong Shao
SJShunzi Jin
Shunzi Jin
Background. Radiation resistance of lung cancer cells is a vital factor affecting the curative effect of lung cancer. Transcription factor GATA3 is involved in cell proliferation, invasion, and migration and is significantly expressed in a variety of malignancies. However, the molecular mechanism governing GATA3 regulation in lung cancer cells’ radiation resistance is unknown. Methods. Radiation‐resistant cell models (A549‐RR and H1299‐RR) were made using fractionated high‐dose irradiation. Use clone formation, CCK‐8, F‐actin staining, cell cycle detection, and other experiments to verify whether the model is successfully constructed. Cells were transiently transfected with knockdown or overexpression plasmid. To explore the relationship between GATA3/H3K4me3 and target genes, we used ChIP‐qPCR, ChIP‐seq, and dual luciferase reporter gene experiments. Xenograft tumor models were used to evaluate the effect of GATA3 depletion on the tumorigenic behavior of lung cancer cells. Results. We report that transcription factors GATA3 and H3K4me3 coactivate NRP1 gene transcription when A549 cells develop radiation resistance. However, the mechanism of radiation resistance in H1299 cells is that GATA3 acts as a transcription inhibitor. The decrease of GATA3 will promote the increase of NRP1 transcription, in which H3K4me3 does not play a leading role. Conclusions. GATA3, an upstream transcriptional regulator of NRP1 gene, regulates the radioresistance of A549 and H1299 cells by opposite mechanisms, which provides a new target for radiotherapy of lung cancer.

3 November 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
HDHengqi Deng
Hengqi Deng
YWYu Wang
Yu Wang
XCXiaoyu Chang
Xiaoyu Chang
XWXinyan Wang
Xinyan Wang
MWMingwei Wang
Mingwei Wang
SJShunzi Jin
Shunzi Jin
Radiotherapy (RT) is a cornerstone of cancer treatment, but intrinsic and acquired radioresistance remain major barriers to the therapeutic efficacy of RT. The capacity of tumor cells to repair radiation-induced DNA damage is a major determinant of treatment response. Post-translational modifications (PTMs) constitute a dynamic regulatory layer of the DNA damage response, influencing damage sensing, chromatin remodeling, repair-factor stability and recruitment, and repair pathway choice. This review examines how interacting PTMs regulate key repair nodes in homologous recombination (HR), canonical non-homologous end joining (c-NHEJ), alternative end joining (alt-EJ), base excision repair/single-strand break repair (BER/SSBR), and the Fanconi anemia (FA) pathway, with particular emphasis on multilayered PTM regulation of individual repair proteins and PTM crosstalk between different repair factors. We further compare PTM regulation of shared repair nodes in tumor and normal cells or tissues and discuss how differential dependence on common repair programs may influence therapeutic selectivity. Finally, PTM-targeted radiosensitization is evaluated in the context of the tumor–normal therapeutic window, with explicit distinction between active normal-tissue protection, preserved normal-tissue tolerance, and treatment-associated toxicity. Collectively, current evidence suggests the possibility of preferentially disrupting tumor DNA repair while limiting normal-tissue injury in selected settings.

20 November 2025 in Genes
Verified
Journal Article
Open access
PDF file
LYLi Yunze
Li Yunze
WKWei Kong
Wei Kong
HZHanqi Zhang
Hanqi Zhang
XWXinfeng Wei
Xinfeng Wei
JYJunxuan Yi
Junxuan Yi
Duo YuDuo Yu
Duo Yu
Idiopathic pulmonary fibrosis (IPF) is a fatal and progressive lung disorder. Its pathological process involves persistent epithelial damage, ongoing inflammation, and dysregulated tissue repair. Currently, there are no effective treatment methods to improve patient survival. However, post-translational modifications (PTMs) have gradually garnered widespread attention. They are the processes by which various chemical groups are added to or removed from proteins’ amino acid side chains or the N- or C-terminal ends of the polypeptide chain following synthesis. Additionally, they can regulate the energy supply of cells, regulate the cell cycle, and affect important signaling pathways such as TGF-β. This review systematically summarizes different categories of PTMs, organizes the PTMs involved in various injury stages of IPF, outlines the roles of different cells throughout the process, and analyzes future clinical diagnosis and treatment strategies as well as intervention targets for IPF, providing guiding significance for the systematic intervention of IPF in the future.